GUTS (Fractyl Health, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by GUTS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | WILLIAM BRADLEY | Director | Buy | — | — |
| 2026-06-15 | Ajay Royan | Director | Buy | — | — |
| 2026-06-11 | Ajay Royan | Director | A | — | — |
| 2026-06-11 | Christopher Charles Thompson | Director | A | — | — |
| 2026-06-11 | CLIVE MEANWELL | Director | A | — | — |
| 2026-06-11 | WILLIAM BRADLEY | Director | Buy | — | — |
| 2026-06-11 | Samuel Conaway | Director | A | — | — |
| 2026-06-11 | Marc Elia | Director | A | — | — |
| 2026-06-11 | Kelly Ann Barnes | Director | A | — | — |
| 2026-06-11 | Ian Sheffield | Director | Buy | — | — |
| 2026-06-11 | Harith Rajagopalan | Chief Executive Officer | Buy | — | — |
| 2026-06-09 | Weber Lara Smith | Chief Financial Officer | Buy | — | — |
| 2026-01-14 | Weber Lara Smith | Chief Financial Officer | A | — | — |
| 2025-12-17 | Harith Rajagopalan | Chief Executive Officer | A | — | — |
| 2025-12-17 | Sarah Toomey | General Counsel | A | — | — |
| 2025-12-17 | Jay David Caplan | President, Chief Product Off. | A | — | — |
| 2025-12-08 | Harith Rajagopalan | Chief Executive Officer | Buy | — | — |
| 2025-09-04 | Ian Sheffield | Director | A | — | — |
| 2025-09-04 | Christopher Charles Thompson | Director | A | — | — |
| 2025-06-13 | AMY W SCHULMAN | Director | A | — | — |
| 2025-06-13 | CLIVE MEANWELL | Director | A | — | — |
| 2025-06-13 | Kelly Ann Barnes | Director | A | — | — |
| 2025-06-13 | Samuel Conaway | Director | A | — | — |
| 2025-06-13 | WILLIAM BRADLEY | Director | A | — | — |
| 2025-06-13 | Marc Elia | Director | A | — | — |
| 2025-06-13 | Ajay Royan | Director | A | — | — |
| 2025-03-18 | Samuel Conaway | Director | — | — | — |
| 2025-03-18 | Kelly Ann Barnes | Director | Buy | — | — |
| 2025-03-18 | Ajay Royan | Director | Buy | — | — |
| 2025-03-17 | WILLIAM BRADLEY | Director | Buy | — | — |
| 2025-03-17 | AMY W SCHULMAN | Director | Buy | — | — |
| 2025-03-17 | Samuel Conaway | Director | Buy | — | — |
| 2025-03-03 | Timothy Kieffer | Chief Scientific Officer | A | — | — |
| 2025-03-03 | Jay David Caplan | President, Chief Product Off. | A | — | — |
| 2025-03-03 | Sarah Toomey | General Counsel | A | — | — |
| 2025-03-03 | Harith Rajagopalan | Chief Executive Officer | A | — | — |
| 2025-03-03 | Lisa Davidson | Chief Financial Officer | A | — | — |
| 2025-02-03 | Jay David Caplan | President, Chief Product Off. | MIXED | — | — |
| 2025-02-03 | Harith Rajagopalan | Chief Executive Officer | MIXED | — | — |
| 2024-11-13 | Jay David Caplan | President, Chief Product Off. | MIXED | — | — |
| 2024-11-13 | Harith Rajagopalan | Chief Executive Officer | MIXED | — | — |
| 2024-09-13 | Jay David Caplan | President, Chief Product Off. | MIXED | — | — |
| 2024-04-02 | Adrian Kimber | Chief Commercial Officer | A | — | — |
| 2024-02-08 | Corebridge DECO II, LLC | 10%+ Owner | C | — | — |
| 2024-02-08 | M28 Capital Management LP | Director | MIXED | — | — |
| 2024-02-08 | Ajay Royan | Director | MIXED | — | — |
| 2024-02-08 | Harith Rajagopalan | Chief Executive Officer | C | — | — |
| 2024-02-08 | Deerfield Mgmt III, L.P. | 10%+ Owner | C | — | — |
| 2024-02-08 | CLIVE MEANWELL | Director | C | — | — |
| 2024-02-08 | GC Entrepreneurs Fund V, LP | 10%+ Owner | C | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,412,201 | — |
| — | Director | 5,201,202 | — |
| — | 10%+ Owner | 4,784,323 | — |
| — | 10%+ Owner | 4,770,901 | — |
| — | — | 4,673,870 | — |
| — | Director | 1,389,451 | — |
| — | 10%+ Owner | 834,254 | — |
| — | Chief Executive Officer | 832,728 | — |
| — | 10%+ Owner | 673,391 | — |
| — | President, Chief Product Off. | 533,822 | — |
| — | 10%+ Owner | 283,878 | — |
| — | Director | 277,890 | — |
| — | 10%+ Owner | 199,257 | — |
| — | Director | 149,138 | — |
| — | Director | 35,000 | — |
| — | Director | 31,000 | — |
| — | Chief Financial Officer | 20,000 | — |
| — | Director | 8,550 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GUTS quote page; the site-wide leaderboard is on the insider transactions hub.